This Oncoimmune drug looks pretty impressive from their trial results. I immediately wonder what its safety profile is, how much it costs to produce it, its MOA (which looks very different from Leronlimab's), how it is administered and does it have the universality to treat as many indications as Leronlimab?

Also, what does it mean for its development after being acquired by Merck. Do shareholders become diluted into Merck's whole financials and revenues or what?

Interesting story.